Securities code: 600668 securities abbreviation: Zhejiang Jianfeng Group Co.Ltd(600668) No.: pro 2021-024
Zhejiang Jianfeng Group Co.Ltd(600668)
Stock trading risk warning announcement
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
The company’s share price has a large increase in the short term, and there is a secondary market transaction risk
The daily closing price of the company’s shares rose within four consecutive trading days on December 27, December 28, December 29 and December 30, 2021, with a cumulative deviation of 39.99% from the Shanghai stock index, 37.22% from the cement industry index and a cumulative turnover rate of 30.7%. As of December 30, 2021, the closing price of the company’s shares has increased by 46.44% compared with the closing price on December 26, 2021. The current P / E ratio of the company is significantly higher than the average level of the cement industry. The company respectfully invites investors to pay attention to the transaction risks in the secondary market, make rational decisions and invest prudently.
The company’s latest net profit and net profit after deducting non recurring profits and losses both fell year-on-year
From January to September 2021, the company realized a net profit attributable to shareholders of listed companies of RMB 424 million, a decrease of 17.82% over the same period of last year, and the net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was RMB 412 million, a decrease of 9.25% over the same period of last year.
Risk of decline in operating performance of subsidiaries Jianfeng pharmaceutical and Shanghai North Carolina
In 2020, Jianfeng pharmaceutical achieved a net profit of 18.5885 million yuan, a decrease of 17.24% compared with 2019, and Shanghai North Carolina achieved a net profit of -25.4226 million yuan, a decrease of 35.22% compared with 2019. In the first three quarters of 2021, Jianfeng pharmaceutical realized a net profit attributable to its parent company of 4.9701 million yuan, a decrease of 83.09% over the same period of last year, and Shanghai North Carolina realized a net profit attributable to its parent company of -16.7401 million yuan, a decrease of 258.44% over the same period of last year.
The yield of existing patents is low and the cost is high
The patent (Patent No.: zl201010609467.8) of “new synthesis method of Caron anhydride” invented by Shanghai North Carolina in the early stage has low yield, high cost and no competitive advantage.
The sales revenue of Caron anhydride accounts for a relatively small proportion and the gross profit margin is low, which will not have a significant impact on the operating performance of the company in 2021
In 2021, the sales revenue of carlon anhydride (alias: carlon anhydride) in Shanghai North Carolina was about 0.39% of the company’s total sales revenue in 2020. All sales customers were Chinese customers, and the company could not determine the purpose of customers. The gross profit margin of sales is less than 5% (Unaudited) and 0.1% lower than the company’s net profit in 2020, which will not have a significant impact on the company’s operating performance in 2021.
The recent stock trading of Zhejiang Jianfeng Group Co.Ltd(600668) (hereinafter referred to as ” Zhejiang Jianfeng Group Co.Ltd(600668) ” or “the company”) fluctuated greatly and touched the trading rules of Shanghai Stock Exchange on December 29, 2021. On December 30, the stock price of the company closed again at the limit price. The company now explains the relevant matters and risks as follows. Please pay attention to the secondary market risks, make rational decisions and invest prudently.
1、 The company’s share price has a large increase in the short term, and there is a secondary market transaction risk.
The daily closing price of the company’s shares rose within four consecutive trading days on December 27, December 28, December 29 and December 30, 2021, with a cumulative deviation of 39.99% from the Shanghai stock index, 37.22% from the cement industry index and a cumulative turnover rate of 30.7%. As of December 30, 2021, the closing price of the company’s shares has increased by 46.44% compared with the closing price on December 26, 2021. The current P / E ratio of the company is significantly higher than the average level of the cement industry. The company respectfully invites investors to pay attention to the transaction risks in the secondary market, make rational decisions and invest prudently.
2、 The company’s latest net profit and net profit after deducting non recurring profits and losses both fell year-on-year
At present, the company’s daily operation and external environment have not changed significantly. According to the guidelines for Industry Classification of listed companies issued by the CSRC, the company belongs to the non-metallic mineral products industry (C30). The company’s consolidated financial statements from January to September 2021 had an operating income of RMB 2.581 billion, including the operating income of building materials industry
1.308 billion yuan, accounting for 50.68%; The operating revenue of the pharmaceutical industry was 952 million yuan, accounting for 36.88%. From January to September 2021, the company realized a net profit attributable to shareholders of listed companies of RMB 424 million, a decrease of 17.82% over the same period of last year, and the net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was RMB 412 million, a decrease of 9.25% over the same period of last year.
3、 Risk of decline in operating performance of subsidiaries Jianfeng pharmaceutical and Shanghai North Carolina
Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as “Jianfeng pharmaceutical”), the holding subsidiary of the company, controlled Shanghai Beika Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Shanghai Beika”) by means of share acquisition and capital increase in January 2018. At present, Jianfeng pharmaceutical holds 61.48% equity of Shanghai Beika. In recent years, the state has continuously deepened the reform of the medical and health system. With the continuous promotion of policies such as the two vote system, the consistency evaluation of generic drugs and the centralized procurement with volume, the price of drugs has decreased significantly and the growth rate of operating revenue of the pharmaceutical industry has decreased. In 2020, Jianfeng pharmaceutical achieved a net profit of 18.5885 million yuan, a decrease of 17.24% compared with 2019, and Shanghai North Carolina achieved a net profit of -25.4226 million yuan, a decrease of 35.22% compared with 2019. In the first three quarters of 2021, Jianfeng pharmaceutical realized a net profit attributable to its parent company of 4.9701 million yuan, a decrease of 83.09% over the same period of last year, and Shanghai North Carolina realized a net profit attributable to its parent company of -16.7401 million yuan, a decrease of 258.44% over the same period of last year. The decline in the operating performance of its subsidiaries Jianfeng pharmaceutical and Shanghai North Carolina had an adverse impact on the overall performance of the company.
4、 The yield of existing patents is low and the cost is high
Prior to the acquisition of Jianfeng pharmaceutical, Shanghai North Carolina transferred the production patent of “new synthesis method of uronic acid lactone, carbonic acid, carbonic anhydride and its key intermediates” (application No.: 2011102478118) in March 2013. At present, it does not hold the patent. When using the patent, it needs to be authorized by the patent holder. In addition, the patent (Patent No.: zl201010609467.8) of the “new synthesis method of Caron anhydride” invented by Shanghai North Carolina in the early stage has low yield, high cost and no competitive advantage.
5、 The sales revenue of Caron anhydride accounts for a relatively small proportion and the gross profit margin is low, which will not have a significant impact on the operating performance of the company in 2021
In 2021, the sales revenue of Caron anhydride (alias: Caron anhydride) in Shanghai North Carolina was about 12.7037 million yuan, about 0.39% of the company’s total sales revenue in 2020; All sales customers are Chinese customers. The company cannot determine the purpose of customers. According to the calculation of the company’s financial department, the sales gross profit margin of Caron anhydride is less than 5% (Unaudited), which is less than 0.1% of the company’s net profit in 2020, and will not have a significant impact on the company’s operating performance in 2021.
The company solemnly reminds investors that China Securities News and Shanghai Securities News are the information disclosure newspapers designated by the company, and the website of Shanghai Stock Exchange (www.sse. Com.. CN.) For the information disclosure website designated by the company, the company’s information shall be subject to the announcement published by the company in the above designated media.
The company specially reminds investors to pay attention to the transaction risks in the secondary market, make prudent decisions, invest rationally, improve risk awareness and avoid blindly following the trend.
It is hereby announced
Zhejiang Jianfeng Group Co.Ltd(600668) board of directors December 31, 2001
